title: Aspirin for primary prevention of cardiovascular events in people with diabetes.
authors.affiliation: Department of Medicine, University of North Carolina, Chapel Hill, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Pignone
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Alberts
authors.forename: John A
authors.initials: JA
authors.lastname: Colwell
authors.forename: Mary
authors.initials: M
authors.lastname: Cushman
authors.forename: Silvio E
authors.initials: SE
authors.lastname: Inzucchi
authors.forename: Debabrata
authors.initials: D
authors.lastname: Mukherjee
authors.forename: Robert S
authors.initials: RS
authors.lastname: Rosenson
authors.forename: Craig D
authors.initials: CD
authors.lastname: Williams
authors.forename: Peter W
authors.initials: PW
authors.lastname: Wilson
authors.forename: M Sue
authors.initials: MS
authors.lastname: Kirkman
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D003327:Coronary Disease / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin